10x Genomics(US:TXG) Prnewswire·2026-02-12 21:05Core Insights - 10x Genomics reported a revenue of $166.0 million for Q4 2025, a 1% increase from Q4 2024, and a full-year revenue of $642.8 million, a 5% increase from 2024 [1][2] - The company ended 2025 with $523.4 million in cash and cash equivalents, an increase of $130.0 million from the previous year [1] - 10x Genomics provided a revenue guidance for 2026, expecting between $600 million to $625 million, indicating a potential growth of 0% to 4% over 2025 [1] Financial Performance - Q4 2025 gross margin was 68%, up from 67% in Q4 2024, attributed to lower inventory write-downs and costs [1] - Operating expenses for Q4 2025 were $132.6 million, an 18% decrease from $160.8 million in Q4 2024, mainly due to reduced legal and personnel expenses [1] - The operating loss for Q4 2025 was $19.5 million, significantly improved from a loss of $49.8 million in Q4 2024 [1] Annual Results - For the full year 2025, gross margin was 69%, compared to 68% in 2024, driven by higher license and royalty revenue [1] - Operating expenses for the full year 2025 decreased by 17% to $504.9 million from $609.0 million in 2024, influenced by a gain on litigation settlements [1] - The net loss for 2025 was $43.5 million, a significant reduction from a net loss of $182.6 million in 2024 [1] Strategic Initiatives - The company launched a study with Brigham & Women's Hospital to identify single cell blood-based signatures for autoimmune diseases [1] - A collaboration with Dana-Farber Cancer Institute was initiated to analyze patient tumor samples, marking the start of a multi-year research initiative [1] - Partnerships with the Cancer Research Institute and PharosAI aim to create large AI-ready datasets for cancer research [1]